Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zevra Therapeutics Inc ZVRA

Healthcare
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered... see more

Recent & Breaking News (NDAQ:ZVRA)

Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

GlobeNewswire October 2, 2023

Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference

GlobeNewswire September 20, 2023

Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023

GlobeNewswire September 9, 2023

Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 5, 2023

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

GlobeNewswire August 31, 2023

Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results

GlobeNewswire August 14, 2023

Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster

GlobeNewswire August 7, 2023

Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023

GlobeNewswire August 2, 2023

Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical Conference

GlobeNewswire July 19, 2023

Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023

GlobeNewswire June 20, 2023

Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest

GlobeNewswire June 13, 2023

Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023

GlobeNewswire June 3, 2023

Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results

GlobeNewswire May 15, 2023

Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023

GlobeNewswire May 10, 2023

Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023

GlobeNewswire May 9, 2023

Zevra Announces Board of Directors and Leadership Changes

GlobeNewswire May 8, 2023

Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy

GlobeNewswire May 3, 2023

Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra's Transformation Strategy

GlobeNewswire April 17, 2023

Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy

GlobeNewswire April 4, 2023

Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors

GlobeNewswire March 30, 2023